Jubilant Ingrevia Q2FY26 Concall Decoded – Chemistry, Contracts & a Pinch of Premium Niacinamide
1. Opening Hook
While Europe’s chemical giants are drowning in energy bills and existential dread, Jubilant Ingrevia just posted its highest quarterly revenue in 10 quarters. The Bhartias may not have found the philosopher’s stone, but they’ve clearly mastered profit alchemy — especially when margins stay intact in a global price slump.
With ₹1,200 crore worth of CDMO molecules in the pipeline, Vitamin B3 turning into a skincare influencer, and semiconductor chemistry sneaking into the chat, this call was more Breaking Bad than boring. Read on — because Ingrevia’s next compound might just be money itself. 💸
2. At a Glance
Revenue up 7% YoY: Highest in 10 quarters; clearly, volume > volatility.